A phase 2 trial reported efficacy for advanced fumarate hydratase-deficient renal cell carcinoma using a combination of tislelizumab and lenvatinib. Researchers highlighted high objective response rates, supporting further development in a rare molecular subtype with limited therapeutic options. The study adds to the broader pivot toward immunotherapy-tyrosine kinase inhibitor combinations in renal cancer, particularly for genetically defined disease categories where biology may influence immune engagement. For investors and developers, the key signal is clinical activity in a rare setting, which can expedite follow-on studies if durability and safety remain consistent.